MA45037A - Polythérapie à base d'arnm pour le traitement du cancer - Google Patents
Polythérapie à base d'arnm pour le traitement du cancerInfo
- Publication number
- MA45037A MA45037A MA045037A MA45037A MA45037A MA 45037 A MA45037 A MA 45037A MA 045037 A MA045037 A MA 045037A MA 45037 A MA45037 A MA 45037A MA 45037 A MA45037 A MA 45037A
- Authority
- MA
- Morocco
- Prior art keywords
- rnam
- polytherapy
- cancer treatment
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662338496P | 2016-05-18 | 2016-05-18 | |
US201662338483P | 2016-05-18 | 2016-05-18 | |
US201662338505P | 2016-05-18 | 2016-05-18 | |
US201662338467P | 2016-05-18 | 2016-05-18 | |
US201662338507P | 2016-05-18 | 2016-05-18 | |
US201662338506P | 2016-05-18 | 2016-05-18 | |
US201662338501P | 2016-05-18 | 2016-05-18 | |
US201662338530P | 2016-05-19 | 2016-05-19 | |
US201662404173P | 2016-10-04 | 2016-10-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA45037A true MA45037A (fr) | 2019-03-27 |
Family
ID=59009789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA045037A MA45037A (fr) | 2016-05-18 | 2017-05-18 | Polythérapie à base d'arnm pour le traitement du cancer |
Country Status (7)
Country | Link |
---|---|
US (4) | US10335486B2 (fr) |
EP (1) | EP3458092A1 (fr) |
JP (2) | JP2019519516A (fr) |
AU (2) | AU2017268399B2 (fr) |
CA (1) | CA3024509A1 (fr) |
MA (1) | MA45037A (fr) |
WO (1) | WO2017201352A1 (fr) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
RS63030B1 (sr) | 2015-09-17 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava |
WO2017070613A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccin contre le cytomégalovirus humain |
EP3364950A4 (fr) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Vaccins contre des maladies tropicales |
HRP20220872T1 (hr) | 2015-10-22 | 2022-12-23 | Modernatx, Inc. | Cjepiva protiv respiratornih virusa |
PE20181529A1 (es) | 2015-10-22 | 2018-09-26 | Modernatx Inc | Vacunas de acido nucleico para el virus varicela-zoster (vzv) |
PE20181300A1 (es) | 2015-11-02 | 2018-08-09 | Five Prime Therapeutics Inc | Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer |
MD3386484T2 (ro) | 2015-12-10 | 2022-11-30 | Modernatx Inc | Compoziții și metode de livrare a unor agenți terapeutici |
EP3394093B1 (fr) | 2015-12-23 | 2022-01-26 | Modernatx, Inc. | Procédés d'utilisation de polynucléotides codant pour un ligand ox40 |
US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
CA3024917A1 (fr) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Combinaisons d'arnm codant pour des polypeptides de modulation immunitaire et leurs utilisations |
CA3024509A1 (fr) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polytherapie a base d'arnm pour le traitement du cancer |
MX2019002904A (es) | 2016-09-14 | 2019-09-26 | Modernatx Inc | Composiciones de arn de alta pureza y métodos para su preparación. |
WO2018075980A1 (fr) | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Vaccin contre le cytomégalovirus humain |
CN110167587A (zh) | 2016-11-11 | 2019-08-23 | 摩登纳特斯有限公司 | 流感疫苗 |
EP3551193A4 (fr) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | Vaccins à acide nucléique contre des virus respiratoires |
WO2018111967A1 (fr) | 2016-12-13 | 2018-06-21 | Modernatx, Inc. | Purification par affinité d'arn |
US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
JP7332478B2 (ja) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子製剤 |
WO2018170260A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus respiratoire syncytial |
WO2018170245A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin à large spectre contre le virus de la grippe |
US11752206B2 (en) * | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
ES2911186T3 (es) | 2017-03-15 | 2022-05-18 | Modernatx Inc | Formas cristalinas de aminolípidos |
WO2018170347A1 (fr) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Vaccins à base d'arn contre des maladies zoonotiques |
WO2018187590A1 (fr) | 2017-04-05 | 2018-10-11 | Modernatx, Inc. | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
AU2018258661A1 (en) | 2017-04-28 | 2019-10-17 | Five Prime Therapeutics, Inc. | Methods of treatment with CD80 extracellular domain polypeptides |
WO2018232357A1 (fr) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Formulations d'arn |
EP3668977A4 (fr) | 2017-08-18 | 2021-04-21 | Modernatx, Inc. | Procédés analytiques par hplc |
WO2019036685A1 (fr) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | Procédés pour analyse par clhp |
JP7408098B2 (ja) | 2017-08-18 | 2024-01-05 | モデルナティエックス インコーポレイテッド | Rnaポリメラーゼバリアント |
EP3675817A1 (fr) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Procédés de fabrication de nanoparticules lipidiques |
WO2019055807A1 (fr) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | Vaccins à arn contre le virus zika |
US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
CA3112781A1 (fr) * | 2018-09-14 | 2020-03-19 | Modernatx, Inc. | Procedes et compositions pour le traitement du cancer faisant appel a des agents therapeutiques a base d'arnm |
JP2022513888A (ja) * | 2018-12-14 | 2022-02-09 | プロヴィヴァ セラピューティクス (ホン コン) リミテッド | Il-15組成物およびその使用方法 |
US20200360481A1 (en) * | 2019-01-08 | 2020-11-19 | Modernatx, Inc. | USE OF MRNAS ENCODING OX40L, IL-23 AND IL-36gamma IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE FOR TREATING CANCER |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
US11926817B2 (en) | 2019-08-09 | 2024-03-12 | Nutcracker Therapeutics, Inc. | Microfluidic apparatus and methods of use thereof |
CN110689920B (zh) * | 2019-09-18 | 2022-02-11 | 上海交通大学 | 一种基于深度学习的蛋白质-配体结合位点预测方法 |
WO2021055833A1 (fr) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Composés lipidiques de queue ramifiés et compositions pour l'administration intracellulaire d'agents thérapeutiques |
CA3161668A1 (fr) | 2019-12-20 | 2021-06-24 | Nammi Therapeutics, Inc. | Compositions liposomales formulees et/ou co-formulees contenant des promedicaments agonistes de recepteurs de type toll (« tlr ») utiles dans le traitement du cancer et methodes a ssociees |
JP2023518835A (ja) * | 2020-03-26 | 2023-05-08 | エショー バイオセラピー, インク. | 制御性t細胞の除去用の二重特異性融合タンパク質 |
MX2022013254A (es) | 2020-04-22 | 2023-01-24 | BioNTech SE | Vacuna contra el coronavirus. |
JP2021170968A (ja) * | 2020-04-22 | 2021-11-01 | 国立大学法人 長崎大学 | マウスil−18の製造方法及びそのための組換えdna |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
US20240067684A1 (en) * | 2020-12-23 | 2024-02-29 | Kernal Biologics, Inc. | Constitutively active payloads |
WO2023031394A1 (fr) | 2021-09-03 | 2023-03-09 | CureVac SE | Nouvelles nanoparticules lipidiques pour l'administration d'acides nucléiques |
WO2023056337A1 (fr) * | 2021-09-30 | 2023-04-06 | The Children's Medical Center Corporation | Agoniste de tlr8 pour la modulation d'une réponse immunitaire |
WO2023073228A1 (fr) | 2021-10-29 | 2023-05-04 | CureVac SE | Arn circulaire amélioré pour exprimer des protéines thérapeutiques |
WO2023144330A1 (fr) | 2022-01-28 | 2023-08-03 | CureVac SE | Inhibiteurs de facteurs de transcription codés par un acide nucleique |
WO2023161854A1 (fr) * | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Immunocytokines il-18 spécifiques d'un antigène immun et leurs utilisations |
CN114874104A (zh) * | 2022-04-29 | 2022-08-09 | 湖北英纳氏生物科技有限公司 | 阳离子脂质体sm-102及其类似物的制备方法 |
WO2023227608A1 (fr) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Vaccin à base d'acide nucléique codant pour un polypeptide antigénique fimh d'escherichia coli |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
WO2024089638A1 (fr) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Vaccin à base d'acide nucléique |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5681702A (en) | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
RS51309B (sr) | 1998-12-23 | 2010-12-31 | Pfizer Inc. | Humana monoklonalna antitela za ctla-4 |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
EP1792991A1 (fr) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Anticorps humains contre CTLA-4 et leur utilisation |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
JP2003525222A (ja) | 2000-01-20 | 2003-08-26 | ウニベルジテート チューリッヒ インスティチュート フューア メディツィニーチェ ビロロギー | Il−12をコードする核酸分子の腫瘍内投与 |
US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
SI2439273T1 (sl) | 2005-05-09 | 2019-05-31 | Ono Pharmaceutical Co., Ltd. | Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki |
CA2608474C (fr) | 2005-05-17 | 2019-11-12 | University Of Connecticut | Compositions et methodes d'immunomodulation d'un organisme |
EP1777294A1 (fr) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Le domaine sushi de IL-15Ralpha comme enhancer sélectif et efficace de l'action de f IL-15 grâce à IL-15Rbeta/gamma, et l' hyperagoniste (IL15Ralpha sushi -IL15) comme protéine fusion |
NZ569541A (en) * | 2006-01-13 | 2012-05-25 | Us Gov Health & Human Serv | Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells |
WO2007113648A2 (fr) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Polythérapie à base d'un anticorps anti-ctla4 |
US8586055B2 (en) | 2007-01-12 | 2013-11-19 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | DNA immunization protocols |
ES2470772T3 (es) | 2007-05-11 | 2014-06-24 | Altor Bioscience Corporation | Moléculas de fusión y variantes de IL-15 |
KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 pd-1에 대한 항체 |
JP2010531878A (ja) | 2007-06-27 | 2010-09-30 | マリン ポリマー テクノロジーズ,インコーポレーテッド | IL‐15とIL‐15Rαとの複合体及びその使用 |
ES2573458T3 (es) | 2007-09-14 | 2016-06-08 | Vrije Universiteit Brussel | Mejoramiento de la capacidad estimulatoria de las células T de las células que presentan antígeno humano y su uso en vacunación |
PE20110435A1 (es) | 2008-08-25 | 2011-07-20 | Amplimmune Inc | Composiciones antagonistas del pd-1 |
GB0903325D0 (en) | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
NZ714757A (en) | 2009-08-14 | 2018-07-27 | Us Gov Health & Human Services | Use of il-15 to increase thymic output and to treat lymphopenia |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
EP2918607B1 (fr) | 2010-09-21 | 2017-11-08 | Altor BioScience Corporation | Molécules de fusion multimères solubles à base d'il-15, leurs procédés de préparation et d'utilisation |
GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
CN103476943A (zh) | 2011-03-10 | 2013-12-25 | 普罗维克图斯药品公司 | 用于增强治疗癌症的局部和全身性免疫调节疗法的组合 |
DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
EP2537933A1 (fr) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Immunocytokines basées sur le domaine IL-15 et IL-15Ralpha sushi |
EP2766035B1 (fr) * | 2011-10-11 | 2018-03-28 | Universität Zürich Prorektorat MNW | Combinaison médicamenteuse comprenant de l'il-12 et un agent de blocage de molécules inhibitrices des lymphocytes t pour une thérapie anti-tumorale |
JP6448533B2 (ja) | 2012-05-15 | 2019-01-09 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Pd−1/pd−l1シグナル伝達を破壊することによる癌免疫療法 |
WO2014066527A2 (fr) | 2012-10-24 | 2014-05-01 | Admune Therapeutics Llc | Formes d'il-15r alpha, cellules exprimant des formes d'il-15r alpha, et utilisations thérapeutiques d'il-15r alpha et de complexes il-15/il-15r alpha |
JP2016504050A (ja) | 2013-01-17 | 2016-02-12 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド |
MX2015011955A (es) | 2013-03-08 | 2016-04-07 | Novartis Ag | Lipidos y composiciones de lipidos para el suministro de agentes activos. |
EP4032540A1 (fr) | 2013-04-19 | 2022-07-27 | Cytune Pharma | Traitement dérivé de la cytokine avec syndrome de fuite vasculaire réduit |
US20160145355A1 (en) | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
ES2698375T3 (es) | 2013-06-27 | 2019-02-04 | Inst Nat Sante Rech Med | Antagonistas de interleucina 15 (IL-15) y usos de los mismos para el tratamiento de enfermedades autoinmunes y enfermedades inflamatorias |
EP4269441A3 (fr) | 2013-08-08 | 2024-01-24 | Cytune Pharma | Domaine sushi de l'il-15 et de l'il-15ralpha basé sur des modulokines |
US20160184399A1 (en) | 2013-08-08 | 2016-06-30 | Cytune Pharma | Combined pharmaceutical composition |
PL3702373T3 (pl) | 2013-09-13 | 2022-12-05 | Beigene Switzerland Gmbh | Przeciwciała anty-PD1 i ich zastosowanie jako środki terapeutyczne i diagnostyczne |
CN106102774A (zh) | 2013-12-17 | 2016-11-09 | 豪夫迈·罗氏有限公司 | 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法 |
US10206980B2 (en) | 2014-01-08 | 2019-02-19 | Shanghai Hengrui Pharmaceutical Co., Ltd. | IL-15 heterodimeric protein and uses thereof |
EP2915569A1 (fr) | 2014-03-03 | 2015-09-09 | Cytune Pharma | Procédé de purification de conjugués à base Il -15/IL-15Ralpha |
RU2746406C2 (ru) * | 2014-04-23 | 2021-04-13 | МОДЕРНАТиЭкс, ИНК. | Вакцины на основе нуклеиновых кислот |
WO2016018920A1 (fr) | 2014-07-29 | 2016-02-04 | Admune Therapeutics Llc | Régimes d'escalade de dose d'hétérodimère il-15 et il-15 r-alpha pour traiter des troubles |
CA2970385C (fr) | 2014-12-19 | 2023-04-04 | Jiangsu Hengrui Medicine Co., Ltd. | Complexe proteine-interleukine 15 et utilisation associee |
RU2749113C2 (ru) | 2015-04-22 | 2021-06-04 | Куревак Аг | Содержащая рнк композиция для лечения опухолевых заболеваний |
CN112574316A (zh) | 2015-07-02 | 2021-03-30 | 博际生物医药科技(杭州)有限公司 | 用于肿瘤靶向治疗的白细胞介素-15融合蛋白 |
US10858452B2 (en) | 2015-09-16 | 2020-12-08 | Insitut National de la Sante et de la Recherche Medicale (INSERM) | Specific interleukin-15 (IL-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases |
CA2999294A1 (fr) | 2015-09-25 | 2017-03-30 | Altor Bioscience Corporation | Superagoniste d'interleukine-15 renforcant considerablement l'activite greffon contre tumeur |
WO2017062426A1 (fr) | 2015-10-06 | 2017-04-13 | The Wistar Institute Of Anatomy And Biology | Procédés et compositions pour le traitement de tumeurs et de cancers métastasés et résistants |
CA3009123A1 (fr) | 2015-12-18 | 2017-06-22 | Oncosec Medical Incorporated | Constructions plasmidiques pour l'expression de proteines heterologues et leurs procedes d'utilisation |
US20190117690A1 (en) | 2016-04-06 | 2019-04-25 | The University State Of America As Represented By The Secretary Of The Department Of Health And Hum | Use of heterodimeric il-15 in adoptive cell transfer |
US11078247B2 (en) | 2016-05-04 | 2021-08-03 | Curevac Ag | RNA encoding a therapeutic protein |
CA3024509A1 (fr) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polytherapie a base d'arnm pour le traitement du cancer |
CA3024917A1 (fr) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Combinaisons d'arnm codant pour des polypeptides de modulation immunitaire et leurs utilisations |
WO2018013855A2 (fr) | 2016-07-14 | 2018-01-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Schémas de traitement avec le récepteur alpha de il -15/il -15 et leur utilisation avec des vaccins thérapeutiques |
KR102562519B1 (ko) | 2016-10-14 | 2023-08-02 | 젠코어 인코포레이티드 | IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질 |
AU2017345791B2 (en) | 2016-10-21 | 2020-10-22 | Altor Bioscience Corporation | Multimeric IL-15-based molecules |
WO2018161026A1 (fr) | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Compositions d'il-15 et méthodes pour immunothérapie |
-
2017
- 2017-05-18 CA CA3024509A patent/CA3024509A1/fr active Pending
- 2017-05-18 MA MA045037A patent/MA45037A/fr unknown
- 2017-05-18 EP EP17728002.1A patent/EP3458092A1/fr not_active Withdrawn
- 2017-05-18 WO PCT/US2017/033425 patent/WO2017201352A1/fr unknown
- 2017-05-18 AU AU2017268399A patent/AU2017268399B2/en active Active
- 2017-05-18 JP JP2018560865A patent/JP2019519516A/ja active Pending
-
2018
- 2018-06-01 US US15/996,146 patent/US10335486B2/en active Active
-
2019
- 2019-06-28 US US16/457,300 patent/US10973917B2/en active Active
-
2021
- 2021-03-16 US US17/202,829 patent/US11660341B2/en active Active
-
2022
- 2022-08-25 JP JP2022134046A patent/JP2022177007A/ja active Pending
-
2023
- 2023-03-27 US US18/190,453 patent/US20230346928A1/en active Pending
- 2023-04-05 AU AU2023202107A patent/AU2023202107A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220096630A1 (en) | 2022-03-31 |
US11660341B2 (en) | 2023-05-30 |
EP3458092A1 (fr) | 2019-03-27 |
JP2019519516A (ja) | 2019-07-11 |
US10973917B2 (en) | 2021-04-13 |
JP2022177007A (ja) | 2022-11-30 |
US20230346928A1 (en) | 2023-11-02 |
AU2023202107A1 (en) | 2023-05-25 |
US20180369374A1 (en) | 2018-12-27 |
US10335486B2 (en) | 2019-07-02 |
AU2017268399A1 (en) | 2019-01-17 |
AU2017268399B2 (en) | 2023-01-12 |
CA3024509A1 (fr) | 2017-11-23 |
WO2017201352A1 (fr) | 2017-11-23 |
US20200054747A1 (en) | 2020-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45037A (fr) | Polythérapie à base d'arnm pour le traitement du cancer | |
MA49144A (fr) | Polythérapies pour le traitement du cancer | |
MA45192A (fr) | Traitement d'association | |
MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
MA45429A (fr) | Polythérapie pour le traitement du cancer | |
MA55697A (fr) | Molécules d'anticorps pour le traitement du cancer | |
MA47501A (fr) | Dérivé de di-nucléotides cycliques pour le traitement du cancer | |
MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
MA48637A (fr) | Polythérapies pour le traitement du cancer | |
MA43000A (fr) | Polythérapie pour le traitement de tumeurs malignes | |
MA41555A (fr) | Polythérapie pour le traitement du cancer | |
MA50409A (fr) | Polythérapies pour le traitement du cancer | |
MA44699A (fr) | Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer | |
MA46652A (fr) | Polythérapie pour l'inhibition de c3 | |
MA41449A (fr) | Polythérapies pour le traitement de cancers | |
MA51139A (fr) | Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer | |
MA41123A (fr) | Polythérapie pour le traitement du cancer | |
FR3050672B1 (fr) | Automate pour le traitement d'une surface | |
MA54925A (fr) | Compositions pour le traitement de troubles acido-basiques | |
MA42999A (fr) | Polythérapie pour le traitement de malignités | |
MA47408A (fr) | Traitement du cancer | |
MA43170A (fr) | Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer | |
MA46062A (fr) | Traitement par ascaroside de l'oesophagite à éosinophiles | |
MA52627A (fr) | Traitement du cancer | |
MA45973A (fr) | Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple |